Analysed PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ) News Sources
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
29-10-2025
yahoo.com
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
07-01-2026
yahoo.com
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
11-06-2026
yahoo.com
Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT)
11-06-2026
advfn.com
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
23-04-2026
yahoo.com
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
15-05-2026
yahoo.com
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
02-09-2026
yahoo.com
What is the current price of PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ)?
The current price of PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ) is $2.31.
PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ) absolute price change since previous trading day?
The absolute price change of PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ) since the previous trading day is $0.65.
PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ) percentage price change since previous trading day?
The percentage price change of PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ) since the previous trading day is 39.1566%.
What is the most recent average sentiment score for PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ)?
The most recent average sentiment score for PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ)?
The most recent sentiment for PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ) is .
SEC-8K** Filing Available For PURPLE BIOTECH LTD-ADR (PPBT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.